Automation And AI Expansion Will Advance Lab Markets Despite Risks

AnalystHighTarget

Not Invested

Community Contributor

Published

07 Aug 25

AnalystHighTarget's Fair Value

US$16.00

15.5% undervalued

10 Sep

US$13.52

84.4%

-16.2%

84.4%

-16.2%

You can edit this narrative until Aug 7 9:30 PM. Then, changes will post as Updates.

Author's Valuation

US$1615.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$16

15.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.29%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.43%

Calculation

US$26.81m

Earnings '28

48.22x

PE Ratio '28

US$1.29b

Market Cap '28

US$1.29b

Market Cap '28

63.09m

No. shares '28

US$20.49

Share Price '28

US$20.49 Share Price '28

Discounted to 2025 @ 8.65% p.a.

US$15.98

Fair Value '25